EMN 2021 | Treating transplant-eligible myeloma: the future gold standard?
Michele Cavo, MD, PhD, Bologna University School of Medicine, Bologna, Italy, discusses the latest developments in the treatment of multiple myeloma. In particular, Prof. Cavo highlights results from the final analysis of the EMN02/HO95 trial (NCT01208766) which investigated lenalidomide, bortezomib and dexamethasone (RVd) consolidation with lenalidomide maintenance versus lenalidomide maintenance alone. Lenalidomide is currently the only novel agent approved for maintenance therapy for patients receiving an autologous stem cell transplantation by the European Medicines Agency (EMA), however may doublet and triplet regimes are currently being evaluated in trials. Finally, Prof. Cavo discusses the importance of achieving measurable residual disease (MRD)-negativity and the move towards MRD-driven therapies. This interview took place during the 2021 European Myeloma Network (EMN) congress.
